| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1997;95:2015-2021.)
© 1997 American Heart Association, Inc.
Articles |
Major Benefit From Antiplatelet Therapy for Patients at High Risk for Adverse Cardiac Events After Coronary Palmaz-Schatz Stent Placement
Analysis of a Prospective Risk Stratification Protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial
From the 1. Medizinische Klinik (H.S., M.H., H.W., A.S.) and Institut für Medizinische Statistik und Epidemiologie (K.U.), Klinikum rechts der Isar, Technische Universität München, Germany.
Correspondence to Dr Helmut Schühlen, 1. Medizinische Klinik der Technischen Universität München, Klinikum rechts der Isar, Ismaninger Str 22, 81675 München, Germany.
Background The Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial is a randomized study in which antiplatelet therapy is compared with anticoagulant therapy after coronary stent placement, showing a significantly lower rate of noncardiac and cardiac events with antiplatelet therapy. The present study is a report of the analysis of a prospective risk stratification protocol in the ISAR Trial and the association with the incidence of adverse cardiac events and stent vessel occlusion.
Methods and Results In all 517 patients randomized in the ISAR Trial, risk stratification was done with a list of 18 clinical, procedural, and angiographic variables: 165 patients with two or fewer criteria were classified as low risk, 148 patients with three criteria were classified as intermediate risk, and 204 patients with four or more criteria were classified as high risk. Within a 30-day follow-up, cardiac event rate (death, myocardial infarction, repeat intervention) was 6.4% for high-risk, 3.4% for intermediate-risk, and 0% for low-risk patients (P<.01). Stent vessel occlusion occurred in 5.9%, 2.7%, and 0%, respectively (P<.01). There was no significant difference between anticoagulant and antiplatelet therapy in the low- and intermediate-risk groups. In high-risk patients, however, the cardiac event rate was 12.6% with anticoagulant therapy and 2.0% with antiplatelet therapy (P=.007), and the rate of stent vessel occlusion was 11.5% and 0%, respectively (P<.001).
Conclusions This risk stratification protocol can help to identify patients at risk for adverse cardiac events and stent vessel occlusion. Patients in the high-risk group had the most benefit from antiplatelet therapy. These data suggest that antiplatelet therapy is the therapy of choice after coronary stenting specifically for patients with acute ischemic syndromes, difficult procedures, or suboptimal final results.
Key Words: stents • platelet aggregation inhibitors • anticoagulants • coronary disease • prognosis
This article has been cited by other articles:
 |
|
 |
|
  N.G. Uren, S.P. Schwarzacher, J.A. Metz, D.P. Lee, Y. Honda, A.C. Yeung, P.J. Fitzgerald, and P.G. Yock Predictors and outcomes of stent thrombosis. An intravascular ultrasound registry Eur. Heart J., January 2, 2002; 23(2): 124 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Schuhlen, A. Kastrati, J.u. Pache, J. Dirschinger, and A. Schomig Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen J. Am. Coll. Cardiol., June 15, 2001; 37(8): 2066 - 2073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Nissen and P. Yock Intravascular Ultrasound : Novel Pathophysiological Insights and Current Clinical Applications Circulation, January 30, 2001; 103(4): 604 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Al Suwaidi, P. B. Berger, and D. R. Holmes Jr Coronary Artery Stents JAMA, October 11, 2000; 284(14): 1828 - 1836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gyongyosi, P. Yang, A. Khorsand, D. Glogar, on behalf of the Austrian Wiktor Stent Study Group, and European Paragon Stent Investigators Longitudinal straightening effect of stents is an additional predictor for major adverse cardiac events J. Am. Coll. Cardiol., May 1, 2000; 35(6): 1580 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dirschinger, A. Kastrati, F.-J. Neumann, P. Boekstegers, S. Elezi, J. Mehilli, H. Schuhlen, J. Pache, E. Alt, R. Blasini, et al. Influence of Balloon Pressure During Stent Placement in Native Coronary Arteries on Early and Late Angiographic and Clinical Outcome : A Randomized Evaluation of High-Pressure Inflation Circulation, August 31, 1999; 100(9): 918 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Urban, C. Macaya, H.-J. Rupprecht, F. Kiemeneij, H. Emanuelsson, A. Fontanelli, M. Pieper, T. Wesseling, L. Sagnard, and f. t. M. Investigators Randomized Evaluation of Anticoagulation Versus Antiplatelet Therapy After Coronary Stent Implantation in High-Risk Patients : The Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS) Circulation, November 17, 1998; 98(20): 2126 - 2132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Schuhlen, A. Kastrati, J. Dirschinger, J. Hausleiter, S. Elezi, A. Wehinger, J. Pache, M. Hadamitzky, and A. Schomig Intracoronary Stenting and Risk for Major Adverse Cardiac Events During the First Month Circulation, July 14, 1998; 98(2): 104 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kereiakes, A. M. Lincoff, D. P. Miller, J. E. Tcheng, C. F. Cabot, K. M. Anderson, H. F. Weisman, R. M. Califf, and E. J. Topol Abciximab Therapy and Unplanned Coronary Stent Deployment : Favorable Effects on Stent Use, Clinical Outcomes, and Bleeding Complications Circulation, March 10, 1998; 97(9): 857 - 864. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. F. Baker JR Thrombosis and Hemostasis in Cardiology: Review of Pathophysiology and Clinical Practice (Part I) Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 51 - 75. [Abstract] [PDF]
|
|